Generic Levaquin Availability
Last updated on May 7, 2025.
Levaquin is a brand name of levofloxacin, approved by the FDA in the following formulation(s):
LEVAQUIN (levofloxacin - injectable;injection)
-
Manufacturer: JANSSEN PHARMS
Approval date: December 20, 1996
Strength(s): EQ 500MG/20ML (EQ 25MG/ML) (discontinued) [RLD] [AP], EQ 750MG/30ML (EQ 25MG/ML) (discontinued) [RLD] [AP]
LEVAQUIN (levofloxacin - solution;oral)
-
Manufacturer: JANSSEN PHARMS
Approval date: October 21, 2004
Strength(s): 250MG/10ML (discontinued) [RLD] [AA]
LEVAQUIN (levofloxacin - tablet;oral)
-
Manufacturer: JANSSEN PHARMS
Approval date: December 20, 1996
Strength(s): 250MG (discontinued) [RLD] [AB], 500MG (discontinued) [RLD] [AB] -
Manufacturer: JANSSEN PHARMS
Approval date: September 8, 2000
Strength(s): 750MG (discontinued) [RLD] [AB]
All of the above formulations have been discontinued.
Is there a generic version of Levaquin available?
Yes. The following products are equivalent to Levaquin:
levofloxacin injectable;injection
-
Manufacturer: GLAND
Approval date: April 22, 2020
Strength(s): EQ 500MG/20ML (EQ 25MG/ML) [AP], EQ 750MG/30ML (EQ 25MG/ML) [AP] -
Manufacturer: RISING
Approval date: June 20, 2011
Strength(s): EQ 500MG/20ML (EQ 25MG/ML) [AP], EQ 750MG/30ML (EQ 25MG/ML) [AP]
levofloxacin solution;oral
-
Manufacturer: LANNETT CO INC
Approval date: May 25, 2018
Strength(s): 250MG/10ML [AA] -
Manufacturer: NOVITIUM PHARMA
Approval date: June 20, 2011
Strength(s): 250MG/10ML [AA]
levofloxacin tablet;oral
-
Manufacturer: AUROBINDO PHARMA LTD
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB] -
Manufacturer: CHARTWELL MOLECULAR
Approval date: March 30, 2012
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB] -
Manufacturer: DR REDDYS LABS INC
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB] -
Manufacturer: GLENMARK PHARMS LTD
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB] -
Manufacturer: HEC PHARM
Approval date: February 5, 2019
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB] -
Manufacturer: HETERO LABS LTD V
Approval date: January 8, 2015
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB] -
Manufacturer: LUPIN
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB] -
Manufacturer: MACLEODS PHARMS LTD
Approval date: March 22, 2012
Strength(s): 500MG [AB], 750MG [AB], 250MG [AB] -
Manufacturer: ORBION PHARMS
Approval date: January 30, 2012
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB] -
Manufacturer: TEVA
Approval date: June 20, 2011
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB] -
Manufacturer: ZYDUS LIFESCIENCES
Approval date: September 7, 2012
Strength(s): 250MG [AB], 500MG [AB], 750MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Levaquin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Levaquin (levofloxacin)
- Levaquin consumer information
- Check interactions
- Compare alternatives
- Reviews (410)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: quinolones and fluoroquinolones
- Breastfeeding
Related treatment guides
Related/similar drugs
Augmentin
Augmentin is a prescription antibiotic combining amoxicillin and clavulanate to treat bacterial ...
Vancomycin
Vancomycin is used to treat infections of the intestines that cause colitis. Learn about side ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Sulfamethoxazole/trimethoprim
Sulfamethoxazole/trimethoprim is used for acne, bacterial infection, bacterial skin infection ...
Amoxicillin/clavulanate
Amoxicillin and clavulanate potassium is a combination antibiotic used to treat bacterial ...
Guaifenesin
Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat. Includes ...
Keflex
Keflex (cephalexin) is used to treat infections caused by bacteria, including respiratory ...
Macrobid
Macrobid (nitrofurantoin) is an antibiotic used to treat urinary tract infections. Includes side ...
Ceftriaxone
Ceftriaxone is used for bacteremia, bacterial endocarditis prevention, bacterial infection, bone ...
Clindamycin
Clindamycin (Cleocin) is used to treat serious infections caused by bacteria. Includes clindamycin ...
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
AA | Products in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved. |
AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
AP | Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.